Inhibitors of ALK tyrosine kinase activity have been well studied in a different set of cancers that do not express intact ALK, but instead express oncogenic ALK fusion proteins in the cytoplasm, particularly non–small cell lung cancer (NSCLC)11,12. Here, ALK is linked to cancer.